Activating FGFR2 mutations commonly found in endometrial cancer (such as S252W, N549K) similarly enhance receptor kinase activity, thereby activating the PI3K-AKT-mTOR pathway to promote cell proliferation and metabolic reprogramming, while regulating cell cycle-related gene expression through the MAPK pathway [110]. This evidence concerns the gene FGFR2 and endometrial cancer.